Serenatis Bio
- Biotech or pharma, therapeutic R&D
Serenatis Bio is a start-up biotech developing three novel drugs to treat obsessive-compulsive disorder (OCD), a common yet poorly treated and devastating mental illness with huge unmet need and commercial opportunity. Each drug has a different mechanism of action - targeting glutamate and dopamine receptors - using precision medicine to identify which OCD patients will respond to which drug.
Address
CambridgeUnited Kingdom
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}